News • 18-4-2012

Efficacy of Omega-3 fatty acid supplements

Sometimes ‘evidence is tumbling over evidence’. In an overview Kromhout and al in the March 2012 issue of Eur Heart Journal the authors “encourage the use of omega-3 fatty acids supplementation in patients with coronary artery disease or after myocardial infarction and possibly in those with heart failure, as suggested by the current guideline.” Read more
News • 18-4-2012

Dual antiplatelet therapy

Based on previous studies, guidelines advocated to treat patients after stenting with dual antiplatelet therapy for at least one year. This large trial, including patients receiving a bare metal stent as well as different types of coated stents shows that 6 months of dual antiplatelet therapy would be sufficient.
Read more

Resistant hypertension: Incidence and prognosis

4-4-2012 • Daugherty SL et al. Circulation. 2012 Apr 3
This retrospective cohort study provides insight into the incidence and prognosis of resistant hypertension. Greater efforts should be made to improve outcomes in patients with resistant hypertension to decrease the risk of cardiovascular events.
Read more
Webcast •

Problems with oral anticoagulants in clinical practice

Dr. Fokko de Haan (Germany) discusses daily problems with the new oral anticoagulants. Watch
Webcast •

What do GPs need to know about this new CVD epidemic

Prof. Richard McManus (Birmingham, United Kingdom) explains what CKD is and how it should be treated, from the GP viewpoint. Watch

Association between chlorthalidone treatment of systolic hypertension and long-term survival

11-1-2012 • Kostis JB et al, JAMA. 2011;306(23):2588-93
In the SHEP trial, treatment of isolated systolic hypertension with chlorthalidone stepped-care therapy for 4.5 years was associated with longer life expectancy at 22 years of follow-up.
Read more
News • 18-4-2012

Dabigatran summary. Meta-analysis of noninferiority randomized controlled trials

This analysis is driven primarily by the RE-LY trial,(1) which contributes 75% of the weight to the overall effect size. It is noteworthy that the results are rendered non-significant (OR 1.16; 95%CI 0.69 to 1.94) when RE-LY is excluded from the analysis. Read more
News • 18-4-2012

Treatment of stable angina

In contrast to treatment of acute coronary syndrome in which coronary atherosclerosis is complicated by plaque rupture followed by thrombocyte clotting, there is mounting evidence for lack of PCI benefit in stable ischemic heart disease (not complicated by thrombocyte clotting). This meta-analysis is the last in a row of studies and meta-analyses showing that optimal medical therapy (OMT) alone is non-inferior to OMT in addition to coronary revascularization with PCI Read more
Webcast •

The future of lipid management in stroke

Prof. Pierre Amarenco (Paris, France) describes how stroke can be prevented with statins and which patients already having stroke should receive statins. Watch
Webcast •

Do biomarkers have a role in CVD prediction or follow-up?

Prof. Arno Hoes (Utrecht, The Netherlands) discusses new biomarkers for predicting of future cardiovascular disease being developed in recent years . Watch
Webcast •

My top ten studies in primary care

Prof. Martin Scherer summarizes his favourite publications of primary care studies. Watch
Webcast •

HF Management & Monitoring

Prof. Martin R. Cowie
Good HF management does require a team approach. A nurse-led multidisciplinary programme could be of added value to patients. Watch

Upcoming meetings

Meeting reports & resources

EPCCS 2017 Report of the Cardiovascular Summit held in Dublin, Ireland
EPCCS Guidance Documents Evidence- and meeting-based guidance for primary care
EPCCS 2015 Report of 8th Annual EPCCS meeting held in Prague.
EPCCS 2014 Report of 7th Annual EPCCS meeting held in Brussels.
All meeting reports...